Repeated adjuvant anti-CEA radioimmunotherapy after resection of colorectal liver metastases: Safety, feasibility, and long-term efficacy results of a prospective phase 2 study

Cancer

Volumn 123, Issue 4, 2017, Pages 638-649

  Sahlmann, Carsten O ^a   Homayounfar, Kia ^a   Niessner, Martin ^a   Dyczkowski, Jerzy ^a   Conradi, Lena Christin ^a   Braulke, Friederike ^a   Meller, Birgit ^a   Beißbarth, Tim ^a   Ghadimi, B Michael ^a   Meller, Johannes ^a   Goldenberg, David M ^b,c   Liersch, Torsten ^a  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b CENTER FOR MOLECULAR MEDICINE AND IMMUNOLOGY   (United States)

^c IMMUNOMEDICS INC   (United States)

Author keywords

adjuvant therapy; carcinoembryonic antigen; colorectal liver metastases; labetuzumab; radioimmunotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; CARCINOEMBRYONIC ANTIGEN; CYTARABINE; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; ETOPOSIDE; FLUOROURACIL; IDARUBICIN; IRINOTECAN; LABETUZUMAB I 131; MITOXANTRONE; OXALIPLATIN; UNCLASSIFIED DRUG; VASCULOTROPIN ANTIBODY; LABETUZUMAB; MONOCLONAL ANTIBODY; RADIOACTIVE IODINE;

ADULT; AGED; ARTICLE; BLAST CELL CRISIS; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER RECURRENCE; CAUSE SPECIFIC SURVIVAL; CHEMORADIOTHERAPY; COLORECTAL LIVER METASTASIS; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG SAFETY; FEASIBILITY STUDY; FEMALE; HUMAN; LIVER RESECTION; LUNG MYCOSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIPLE ORGAN FAILURE; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PANCYTOPENIA; PHASE 2 CLINICAL TRIAL; POSTOPERATIVE PERIOD; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RADIOIMMUNOTHERAPY; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA; SEPSIS; ADVERSE EFFECTS; CLINICAL TRIAL; COLORECTAL NEOPLASMS; DISEASE FREE SURVIVAL; IMMUNOLOGY; LIVER NEOPLASMS; MULTIMODALITY CANCER THERAPY; SECONDARY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; CARCINOEMBRYONIC ANTIGEN; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IODINE RADIOISOTOPES; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RADIOIMMUNOTHERAPY;

EID: 85011673020     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.30390     Document Type: Article

References (37)

1. Manfredi S, Lepage C, Hatem C, Coatmeur O, Faivre J, Bouvier AM. Epidemiology and management of liver metastases from colorectal cancer. Ann Surg. 2006;244:254–259.
2. Abdalla EK, Adam R, Bilchik AJ, Jaeck D, Vauthey JN, Mahvi D. Improving resectability of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol. 2006;13:1271–1280.
3. de Jong MC, Pulitano C, Ribero D, et al. Rates and patterns of recurrence following curative intent surgery for colorectal liver metastasis: an international multi-institutional analysis of 1669 patients. Ann Surg. 2009;250:440–448.
4. Nordlinger B, Sorbye H, Glimelius B, et al. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2013;14:1208–1215.
5. Ychou M, Hohenberger W, Thezenas S, et al. A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer. Ann Oncol. 2009;20:1964–1970.
6. 131I-labetuzumab after salvage resection of colorectal metastases in the liver: 5-year safety and efficacy results. J Clin Oncol. 2005;23:6763–6770.
7. 131I-labetuzumab after salvage resection of colorectal liver metastases: comparison of outcome to a contemporaneous control group. Ann Surg Oncol. 2007;14:2577–2590.
8. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999;230:309–318.
9. Gayowski TJ, Iwatsuki S, Madariaga JR, et al. Experience in hepatic resection for metastatic colorectal cancer: analysis of clinical and pathologic risk factors. Surgery. 1994;116:703–710.
10. Fraker PJ, Speck JC Jr. Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril. Biochem Biophys Res Commun. 1978;80 849–857.
11. Hajjar G, Sharkey RM, Burton J, et al. Phase I radioimmunotherapy trial with iodine-131-labelled humanized MN-14 anti-carcinoembryonic antigen monoclonal antibody in patients with metastatic gastrointestinal and colorectal cancer. Clin Colorectal Cancer. 2002;2:31–42.
12. Stabin MG. MIRDOSE. personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 1996;37:538–546.
13. Shen S, DeNardo GL, Sgouros G, O'Donnell RT, DeNardo SJ. Practical determination of patient-specific marrow dose using radioactivity concentration in blood and body. J Nucl Med. 1999;40:2102–2106.
14. Schmiegel W, Pox C, Adler G., et al. S3-Leitlinienkonferenz “Kolorektales Karzinom” 2004. [S3-Guidelines Conference “Colorectal Carcinoma” 2004.] Z Gastroenterol. 2004;42:1129–1177.
15. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079–2088.
16. Greenberg P, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120:2454–2465.
17. Schanz J, Tuchler H, Sole F, et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol. 2012;30:820–829.
18. Gold P, Goldenberg NA. The carcinoembryonic antigen (CEA): past present, and future. McGill J Med. 1997;3:46–66.
19. Rao AV, Akabani G, Rizzieri DA. Radioimmunotherapy for non-Hodgkin's lymphoma. Clin Med Res. 2005;3:157–165.
20. 2 in patients with non-resectable liver metastases from colorectal cancer. Int J Cancer. 1998;75:615–619.
21. Morschhauser F, Kraeber-Bodere F, Wegener WA, et al. High rates of durable responses with anti-CD22 fractionated radioimmunotherapy: results of a multicenter, phase I/II study in non-Hodgkin's lymphoma. J Clin Oncol. 2010;28:3709–3716.
22. 90Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer: a phase 1 trial. Cancer. 2012;118:5497–5506.
23. Cooper DS. Antithyroid drugs. N Engl J Med. 2005;352:905–917.
24. Ngan SY, Burmeister B, Fisher RJ, et al. Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04. J Clin Oncol. 2012;30:3827–3833.
25. Kaminski MS, Estes J, Zasadny KR, et al. Radioimmunotherapy with iodine I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood. 2000;96:1259–1266.
26. Armitage JO, Carbone PP, Connors JM, et al. Treatment-related myelodysplasia and acute leukemia in non-Hodgkin's lymphoma patients. J Clin Oncol. 2003;21:897–906.
27. Schroeder T, Kuendgen A, Kayser S, et al. Therapy-related myeloid neoplasms following treatment with radioiodine. Haematologica. 2012;97:206–212.
28. Sharkey RM, Weadock KS, Natale A, et al. Successful radioimmunotherapy for lung metastasis of human colonic cancer in nude mice. J Natl Cancer Inst. 1991;83:627–632.
29. Araujo RL, Gonen M, Allen P, et al. Positive Postoperative CEA is a strong predictor of recurrence for patients after resection for colorectal liver metastases. Ann Surg Oncol. 2015;22:3087–3093.
30. Kim SY, Kim HJ, Hong YS, et al. Resected colorectal liver metastases: does the survival differ according to postoperative chemotherapy regimen? J Surg Oncol. 2009;100:713–718.
31. Kokudo N, Tada K, Seki M, et al. Proliferative activity of intrahepatic colorectal metastases after preoperative hemihepatic portal vein embolization. Hepatology. 2001;34:267–272.
32. Elias D, de Baere T, Roche A, Mducreux, Leclere J, Lasser P. During liver regeneration following right portal embolization the growth rate of liver metastases is more rapid than that of the liver parenchyma. Br J Surg. 1999;86:784–788.
33. Simoneau E, Aljiffry M, Salman A, et al. Portal vein embolization stimulates tumour growth in patients with colorectal cancer liver metastases. HPB (Oxford). 2012;14:461–468.
34. Goldenberg DM, Sharkey RM, Paganelli G, Barbet J, Chatal JF. Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy. J Clin Oncol. 2006;24:823–834.
35. Govindan SV, Cardillo TM, Moon SJ, Hansen HJ, Goldenberg DM. CEACAM5-targeted therapy of human colonic and pancreatic cancer xenografts with potent labetuzumab-SN-38 immunoconjugates. Clin Cancer Res. 2009;15:6052–6061.
36. Dotan E, Starodub AN, Berlin J, et al. A new anti-CEA-SN-38 antibody-drug conjugate (ADC), IMMU-130, is active in controlling metastatic colorectal cancer (mCRC) in patients (pts) refractory or relapsing after irinotecan-containing chemotherapies: initial results of a phase I/II study [serial online]. J Clin Oncol. 2015;33(suppl). Abstract 2505.
37. Krause P, Flikweert H, Monin M, et al. Increased growth of colorectal liver metastasis following partial hepatectomy. Clin Exp Metastasis. 2013;30:681–693.